Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients

Histology and Histopathology

Volumn 28, Issue 4, 2013, Pages 513-524

  Maciejczyk, Adam ^a   Łacko, Aleksandra ^a,b   Ekiert, Marcin ^a,b   Jagoda, Ewa ^b   Wysocka, Teresa ^b   Matkowski, Rafal ^a,b   Hałoń, Agnieszka ^b   Györffy, Balázs ^c   Lage, Hermann ^d   Surowiak, Pawel ^b  

^a Wroclaw   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; Prognostic biomarker; S100P

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM BINDING PROTEIN; MESSENGER RNA; S100P PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST TUMOR; CANCER STAGING; CELL NUCLEUS; CELL SURVIVAL; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84876424023     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Arumugam T., Simeone D.M., Schmidt A.M. and Logsdon C.D. (2004). S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J. Biol. Chem. 279, 5059-5065.
2. Arumugam T., Simeone D.M., Van Golen K. and Logsdon C.D. (2005). S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 11, 5356-5364.
3. Arumugam T., Ramachandran V. and Logsdon C.D. (2006). Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J. Natl. Cancer Inst. 98, 1806-1818.
4. Barraclough D.L., Sewart S., Rudland P.S., Shoker B.S., Sibson D.R., Barraclough R. and Davies M.P. (2010) Microarray analysis of suppression subtracted hybridisation libraries identifies genes associated with breast cancer progression. Cell Oncol. 32, 87-99.
5. Basu G.D., Azorsa D.O., Kiefer J.A., Rojas A.M., Tuzmen S., Barrett M.T., Trent J.M., Kallioniemi O. and Mousses S. (2008). Functional evidence implicating S100P in prostate cancer progression. Int. J. Cancer 123, 330-339.
6. Dairkee S.H., Sayeed A., Luciani G., Champion S., Meng Z., Jakkula L.R., Feiler H.S., Gray J.W. and Moore D.H. (2009). Immutable functional attributes of histologic grade revealed by contextindependent gene expression in primary breast cancer cells. Cancer Res. 69, 7826-7834.
7. Diederichs S., Bulk E. and Steffen B. (2004). S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 64, 5564-5569.
8. Donato R. (2003). Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 60, 540-551.
9. Dowen S.E., Crnogorac-Jurcevic T., Gangeswaran R., Hansen M., Eloranta J.J., Bhakta V., Brentnall T.A., Lüttges J., Klöppel G. and Lemoine N.R. (2005). Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am. J. Pathol. 166, 81-92.
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-717.
11. Ferlay J.F., Bray P., Pisani P. and Parkin D.M. GLOBOCAN 2002 (2004). Cancer incidence, mortality and prevalence worldwide IARC cancerbase. Lyon. IARC Press.
12. Fuentes M.K., Nigavekar S.S., Arumugam T., Logsdon C.D., Schmidt A.M., Park J.C. and Huang E.H. (2007). RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon Rectum. 50, 1230-1240.
13. Gibadulinova A., Tothova V., Pastorek J. and Pastorekova S. (2011). Transcriptional regulation and functional implication of S100P in cancer. Amino Acids. 41, 885-892.
14. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. and Panel members (2009). Threshold for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann. Oncol. 20, 1319-1329.
15. Guerreiro Da Silva I.D., Hu Y.F. and Russo I.H. (2000). S100P calciumbinding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int. J. Oncol. 16, 231-240.
16. Györffy B., Surowiak P., Kiesslich O., Denkert C., Schäfer R., Dietel M. and Lage H. (2006). Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer 118, 1699-1712.
17. Györffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q. and Szallasi Z. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res. Treat. 123, 725-731.
18. Koltzscher M., Neumann C., Konig S. and Gerke V. (2003) Cadependent binding and activation of dormant ezrin by dimeric S100P. Mol. Biol. Cell. 14, 2372-2384.
19. Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., Misek D.E., Kuick R. and Hanash S. (2003). Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 63, 2649-2657.
20. Mackay A., Jones C., Dexter T., Silva R.L., Bulmer K., Jones A., Simpson P., Harris R.A., Jat P.S., Neville A.M., Reis L.F., Lakhani S.R. and O'Hare M.J. (2003). cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22, 2680-2688.
21. Mousses S., Bubendorf L., Wagner U., Hostetter G., Kononen J., Cornelison R., Goldberger N., Elkahloun A.G., Willi N., Koivisto P., Ferhle W., Raffeld M., Sauter G. and Kallioniemi O.P. (2002): Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 62, 1256-1260.
22. Parkkila S., Pan P.W., Ward A., Gibadulinova A., Oveckova I., Pastorekova S., Pastorek J., Martinez A.R., Helin H.O. and Isola J. (2008). The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin. Pathol. 18, 8:2.
23. Perez E., Romond E. and Suman V. (2007). Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patiens with HER2- positive breast cancer. J. Clin. Oncol. 25, 6s.
24. Sato N., Fukushima N., Matsubayashi H. and Goggins M. (2004). Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 23, 1531-1538.
25. Schor A.P., Carvalho F.M., Kemp C., Silva I.D. and Russo J. (2006). S100P calcium-binding protein expression is associated with highrisk proliferative lesions of the breast. Oncol. Rep. 15, 3-6.
26. Surowiak P., Maciejczyk A., Materna V., Drag-Zalesińska M., Wojnar A., Pudelko M., Kedzia W., Spaczyński M., Dietel M., Zabel M. and Lage H. (2007). Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology 51, 125-128.
27. Tang H., Liu Y.J., Liu M. and Li X. (2007). Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L- OHP. Anticancer Drugs 18, 633-639.
28. Wang G., Platt-Higgins A., Carroll J., de Silva Rudland S., Winstanley J., Barraclough R. and Rudland P.S. (2006). Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 66, 1199-1207.
29. Wang Q., He Z., Gao J., Hu S., Huang M., Liu M., Zheng J. and Tang H. (2008). S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro. Cancer Lett. 272, 277-284.